Article Text

Download PDFPDF
Conditional approval: who knows?
  1. Henry Fok,
  2. Khong Teck,
  3. David Phizackerley, Deputy Editor
  1. St George’s, University of London and King’s College, London, UK
  2. St. George’s, University of London, London, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The arguments for streamlining and speeding up regulatory approval processes for new therapies are well-rehearsed.1 Removing delays facilitates earlier access to new, potentially life-changing medicines for patients who may have few other therapeutic options. In addition, shorter and more specific licensing processes may better support the development of new medicines for small numbers of patients who may have very rare conditions. Nevertheless, at its core, licensing of a medicine involves assessment of data on its quality, safety and efficacy and requires a judgement of the overall risk–benefit balance. The earlier …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.